# The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

> **NCT01842581** · PHASE4 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Hepatic Encephalopathy
- Cirrhosis

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT01842581
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-08
- **Primary completion:** 2014-12-17
- **Final completion:** 2014-12-17
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01842581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01842581, "The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01842581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*